Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...
In Arm 2A of the trial, patients with RT (n=42) received epcoritamab monotherapy in the first-line setting or in second- or later-line settings, with a median follow-up of 22.9 months. In the ...
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
When the federal government starts coming apart at its fiscal seams, Social Security will be the first thing to unravel. It is among the country’s largest financial challenges at over $50 trillion in ...
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for ...
Columbia has always been a place that believes in what is possible. From our bustling university and colleges to our creative businesses, we have built a community where ideas grow and dreams take ...
LEXINGTON, Ky. (Sept. 9, 2025) — Champions Blue LLC’s Board of Governors has endorsed the pre-design and programming phases for a visionary multi-use facility that could feature a dedicated Kentucky ...
Manchester City will want to put the misery of 2024–25 quickly behind them and once again compete for major trophies in 2025–26. Since the turn of the decade, City have become one of the premier ...
Mikel Arteta’s Arsenal were Champions League semifinalists last season. / Catherine Ivill - AMA/Getty Image Arsenal set their sights on the Champions League once again in a pivotal season for Mikel ...
Harden announces the grand opening of Food Basics, the first tenant of Plaza Hawkesbury – Phase III. This ± 32,000 sq. ft. supermarket, renowned for its competitive prices, opened its doors yesterday, ...
A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect. Women’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback